Management of adverse events associated with idelalisib treatment: Expert panel opinion

Leukemia and Lymphoma

Volumn 56, Issue 10, 2015, Pages 2779-2786

  Coutré, Steven E ^a   Barrientos, Jacqueline C ^b   Brown, Jennifer R ^c   De Vos, Sven ^d   Furman, Richard R ^e   Keating, Michael J ^f   Li, Daniel ^g   Obrien, Susan M ^f   Pagel, John M ^h   Poleski, Martin H ⁱ   Sharman, Jeff P ^j   Yao, Nai Shun ^g   Zelenetz, Andrew D ^k  

^a STANFORD CANCER INSTITUTE   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g GILEAD SCIENCES   (United States)

^h SWEDISH MEDICAL CENTER   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j Willamette Valley Cancer Institute and Research Center   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

colitis; diarrhea; Idelalisib, phosphatidylinositol 3 kinase delta (PI3K ) inhibitor; pneumonitis; transaminitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUDESONIDE; DUVELISIB; IDELALISIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PREDNISOLONE; PROTEIN KINASE B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ADVERSE DRUG REACTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; COLON PERFORATION; COLONOSCOPY; DIARRHEA; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DUODENITIS; EMBRYOTOXICITY; FETOTOXICITY; HUMAN; HYPERTRANSAMINASEMIA; INTESTINE PERFORATION; LIVER TOXICITY; MONOTHERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN MANIFESTATION; STEROID THERAPY; TOXIC EPIDERMAL NECROLYSIS; ALGORITHM; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIET THERAPY; DISEASE MANAGEMENT; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXPERT WITNESS; HEMATOLOGIC NEOPLASMS; METABOLISM; MORTALITY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; DIET THERAPY; DISEASE MANAGEMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME INHIBITORS; EXPERT TESTIMONY; HEMATOLOGIC NEOPLASMS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PURINES; QUINAZOLINONES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84941200862     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1022770     Document Type: Review

References (23)

1. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591-594.
2. ZYDELIG (idelalisib tablets). Full prescribing information, Gilead Sciences, Inc., Foster City, CA, 2014.
3. ZYDELIG (idelalisib tablets). Summary of product characteristics, Gilead Sciences International Ltd, Cambridge, UK, 2014.
4. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-1274.
5. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003;3:317-330.
6. Chantry D, Vojtek A, Kashishian A, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997;272:19236-19241.
7. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603-3612.
8. Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002;22:8580-8591.
9. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88-92.
10. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-574.
11. Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008-1018.
12. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370: 997-1007.
13. Data on file. Gilead Sciences, Inc., Foster City, CA, 2014.
14. Flinn I, Oki Y, Patel M, et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-?, inhibitor, in patients with relapsed/refractory iNHL. Blood 2014;124(Suppl. 1): Abstract 802.
15. Uno JK, Rao KN, Matsuoka K, et al. Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110delta. Gastroenterology 2010;139:1642-1653, 1653. e1-6.
16. Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918-2926.
17. Duran I, Goebell PJ, Papazisis K, et al. Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opin Drug Saf 2014;13:361-372.
18. Byrd JC, Woyach JA, Johnson AJ. Translating PI3K-delta inhibitors to the clinic in chronic lymphocytic leukemia: The story of CAL-101 (GS1101). Am Soc Clin Oncol Educ Book 2012;32:691-694.
19. Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078-2088.
20. Jin F, Robeson M, Zhou H, et al. Drug interaction profile of idelalisib and its major metabolit, GS-563117. J Clin Oncol 2014; 32(Suppl.): Abstract 2593.
21. American Cancer Society. Caring for the patient with cancer at home: a guide for patients and families. 2013. Available from: www. cancer. org/acs/groups/cid/documents/webcontent/002818-pdf. pdf
22. National Cancer Institute. Managing chemotherapy side effects: diarrhea. 2012. Available from: www. cancer. gov/cancertopics/coping/chemo-side-effects/diarrhea. pdf
23. Entocorta EC (budesonide). Full prescribing information, AstraZeneca LP, Wilmington, DE, 2011.